1.
Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1.
Markets Covered
1.2.2.
Years Considered for Study
1.2.3.
Key Market Segmentations
2.
Research Methodology
2.1.
Objective of the Study
2.2.
Baseline Methodology
2.3.
Key Industry Partners
2.4.
Major Association and Secondary Sources
2.5.
Forecasting Methodology
2.6.
Data Triangulation & Validation
2.7. Assumptions and
Limitations
3.
Executive Summary
3.1.
Overview of the Market
3.2.
Overview of Key Market Segmentations
3.3.
Overview of Key Market Players
3.4.
Overview of Key Regions/Countries
3.5.
Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5.
Global Multicancer Screening Market Outlook
5.1.
Market Size & Forecast
5.1.1. By Value &
Volume
5.2.
Market Share & Forecast
5.2.1. By Test Type (Laboratory Developed Tests (LDTs), In-Vitro Diagnostics
(IVDs))
5.2.2. By Technology (Next-Generation Sequencing (NGS), Polymerase Chain
Reaction (PCR), Immunohistochemistry (IHC), Fluorescence In-Situ Hybridization
(FISH), and Other Technologies)
5.2.3. By Sample (Tissue, Blood, Saliva and Buccal Swab, and Others)
5.2.4. By Method (DNA, RNA, and Proteins)
5.2.5. By Cancer Type (Breast and Gynecologic, Gastrointestinal, Endocrine,
Genitourinary, Skin, Brain/Nervous System, Sarcoma, Hematological Malignancies,
Lung, Head and Neck, and Other Cancer Types)
5.2.6. By Application (Clinical, Research)
5.2.7. By End User (Hospitals, Diagnostic and Clinical Laboratories, Academic
Research Institutions, and Other End Users)
5.2.8. By Region
5.2.9. By Company (2022)
5.3.
Product Market Map
6. North America Multicancer
Screening Market Outlook
6.1.
Market Size & Forecast
6.1.1. By Value & Volume
6.2.
Market Share & Forecast
6.2.1. By Test Type
6.2.2. By Technology
6.2.3. By Sample
6.2.4. By Method
6.2.5. By Cancer Type
6.2.6. By Application
6.2.7. By End User
6.2.8. By Country
6.3. North America: Country Analysis
6.3.1. United States Multicancer Screening
Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value & Volume
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Test Type
6.3.1.2.2. By Technology
6.3.1.2.3. By Sample
6.3.1.2.4. By Method
6.3.1.2.5. By Cancer Type
6.3.1.2.6. By Application
6.3.1.2.7. By End User
6.3.2. Mexico Multicancer Screening Market Outlook
6.3.2.1. Market Size
& Forecast
6.3.2.1.1. By Value & Volume
6.3.2.2. Market
Share & Forecast
6.3.2.2.1. By Test
Type
6.3.2.2.2. By Technology
6.3.2.2.3. By Sample
6.3.2.2.4. By Method
6.3.2.2.5. By Cancer Type
6.3.2.2.6. By Application
6.3.2.2.7. By End User
6.3.3. Canada Multicancer Screening Market
Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
& Volume
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Test
Type
6.3.3.2.2. By Technology
6.3.3.2.3. By Sample
6.3.3.2.4. By Method
6.3.3.2.5. By Cancer Type
6.3.3.2.6. By Application
6.3.3.2.7. By End User
7. Europe Multicancer
Screening Market Outlook
7.1.
Market Size & Forecast
7.1.1. By Value & Volume
7.2.
Market Share & Forecast
7.2.1. By Test Type
7.2.2. By Technology
7.2.3. By Sample
7.2.4. By Method
7.2.5. By Cancer Type
7.2.6. By Application
7.2.7. By End User
7.2.8. By Country
7.3 Europe:
Country Analysis
7.3.1. France Multicancer
Screening Market Outlook
7.3.1.1. Market Size
& Forecast
7.3.1.1.1. By Value
& Volume
7.3.1.2. Market
Share & Forecast
7.3.1.2.1. By Test Type
7.3.1.2.2. By Technology
7.3.1.2.3. By Sample
7.3.1.2.4. By Method
7.3.1.2.5. By Cancer Type
7.3.1.2.6. By Application
7.3.1.2.7. By End User
7.3.2. Germany Multicancer Screening
Market Outlook
7.3.2.1. Market Size
& Forecast
7.3.2.1.1. By Value
& Volume
7.3.2.2. Market
Share & Forecast
7.3.2.2.1. By Test
Type
7.3.2.2.2. By Technology
7.3.2.2.3. By Sample
7.3.2.2.4. By Method
7.3.2.2.5. By Cancer Type
7.3.2.2.6. By Application
7.3.2.2.7. By End User
7.3.3. United
Kingdom Multicancer Screening Market Outlook
7.3.3.1. Market Size
& Forecast
7.3.3.1.1. By Value
& Volume
7.3.3.2. Market
Share & Forecast
7.3.3.2.1. By Test
Type
7.3.3.2.2. By Technology
7.3.3.2.3. By Sample
7.3.3.2.4. By Method
7.3.3.2.5. By Cancer Type
7.3.3.2.6. By Application
7.3.3.2.7. By End User
7.3.4. Italy Multicancer
Screening Market Outlook
7.3.4.1. Market Size
& Forecast
7.3.4.1.1. By Value
& Volume
7.3.4.2. Market
Share & Forecast
7.3.4.2.1. By Test
Type
7.3.4.2.2. By Technology
7.3.4.2.3. By Sample
7.3.4.2.4. By Method
7.3.4.2.5. By Cancer Type
7.3.4.2.6. By Application
7.3.4.2.7. By End User
7.3.5. Spain Multicancer
Screening Market Outlook
7.3.5.1. Market Size
& Forecast
7.3.5.1.1. By Value
& Volume
7.3.5.2. Market
Share & Forecast
7.3.5.2.1. By Test
Type
7.3.5.2.2. By Technology
7.3.5.2.3. By Sample
7.3.5.2.4. By Method
7.3.5.2.5. By Cancer Type
7.3.5.2.6. By Application
7.3.5.2.7. By End User
8. Asia-Pacific Multicancer
Screening Market Outlook
8.1.
Market Size & Forecast
8.1.1. By Value &
Volume
8.2.
Market Share & Forecast
8.2.1. By Test Type
8.2.2. By Technology
8.2.3. By Sample
8.2.4. By Method
8.2.5. By Cancer Type
8.2.6. By Application
8.2.7. By End User
8.2.8. By Country
8.3.
Asia-Pacific: Country Analysis
8.3.1. China Multicancer
Screening Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value & Volume
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Test Type
8.3.1.2.2. By Technology
8.3.1.2.3. By Sample
8.3.1.2.4. By Method
8.3.1.2.5. By Cancer Type
8.3.1.2.6. By Application
8.3.1.2.7. By End User
8.3.2. India Multicancer
Screening Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value & Volume
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Test Type
8.3.2.2.2. By Technology
8.3.2.2.3. By Sample
8.3.2.2.4. By Method
8.3.2.2.5. By Cancer Type
8.3.2.2.6. By Application
8.3.2.2.7. By End User
8.3.3. South Korea Multicancer
Screening Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value & Volume
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Test Type
8.3.3.2.2. By Technology
8.3.3.2.3. By Sample
8.3.3.2.4. By Method
8.3.3.2.5. By Cancer Type
8.3.3.2.6. By Application
8.3.3.2.7. By End User
8.3.4. Japan Multicancer
Screening Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value & Volume
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Test Type
8.3.4.2.2. By Technology
8.3.4.2.3. By Sample
8.3.4.2.4. By Method
8.3.4.2.5. By Cancer Type
8.3.4.2.6. By Application
8.3.4.2.7. By End User
8.3.5. Australia Multicancer
Screening Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value & Volume
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Test Type
8.3.5.2.2. By Technology
8.3.5.2.3. By Sample
8.3.5.2.4. By Method
8.3.5.2.5. By Cancer Type
8.3.5.2.6. By Application
8.3.5.2.7. By End User
9. South America Multicancer
Screening Market Outlook
9.1.
Market Size & Forecast
9.1.1. By Value &
Volume
9.2.
Market Share & Forecast
9.2.1. By Test Type
9.2.2. By Technology
9.2.3. By Sample
9.2.4. By Method
9.2.5. By Cancer Type
9.2.6. By Application
9.2.7. By End User
9.2.8. By Country
9.3.
South America: Country Analysis
9.3.1. Brazil Multicancer
Screening Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value & Volume
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Test Type
9.3.1.2.2. By Technology
9.3.1.2.3. By Sample
9.3.1.2.4. By Method
9.3.1.2.5. By Cancer Type
9.3.1.2.6. By Application
9.3.1.2.7. By End User
9.3.2. Argentina Multicancer
Screening Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value & Volume
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Test Type
9.3.2.2.2. By Technology
9.3.2.2.3. By Sample
9.3.2.2.4. By Method
9.3.2.2.5. By Cancer Type
9.3.2.2.6. By Application
9.3.2.2.7. By End User
9.3.3. Colombia Multicancer
Screening Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value & Volume
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Test Type
9.3.3.2.2. By Technology
9.3.3.2.3. By Sample
9.3.3.2.4. By Method
9.3.3.2.5. By Cancer Type
9.3.3.2.6. By Application
9.3.3.2.7. By End User
10. Middle East and
Africa Multicancer Screening Market Outlook
10.1. Market Size &
Forecast
10.1.1. By Value &
Volume
10.2.
Market Share & Forecast
10.2.1. By Test Type
10.2.2. By Technology
10.2.3. By Sample
10.2.4. By Method
10.2.5. By Cancer Type
10.2.6. By Application
10.2.7. By End User
10.2.8. By Country
10.3.
MEA: Country Analysis
10.3.1. South Africa Multicancer
Screening Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value & Volume
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Test Type
10.3.1.2.2. By Technology
10.3.1.2.3. By Sample
10.3.1.2.4. By Method
10.3.1.2.5. By Cancer Type
10.3.1.2.6. By Application
10.3.1.2.7. By End User
10.3.2. Saudi Arabia Multicancer
Screening Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value & Volume
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Test Type
10.3.2.2.2. By Technology
10.3.2.2.3. By Sample
10.3.2.2.4. By Method
10.3.2.2.5. By Cancer Type
10.3.2.2.6. By Application
10.3.2.2.7. By End User
10.3.3. UAE Multicancer
Screening Market Outlook
10.3.3.1.Market Size & Forecast
10.3.3.1.1. By Value & Volume
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Test Type
10.3.3.2.2. By Technology
10.3.3.2.3. By Sample
10.3.3.2.4. By Method
10.3.3.2.5. By Cancer Type
10.3.3.2.6. By Application
10.3.3.2.7. By End User
11.
Market Dynamics
11.1. Drivers
11.2. Challenges
12.
Market Trends & Developments
13. PESTLE Analysis
14. Porter’s Five Forces
Analysis
14.1. Competition in the
Industry
14.2. Potential of New
Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute
Product
15.
Competitive Landscape
15.1. Business Overview
15.2. Company Snapshot
15.3. Products & Services
15.4. Financials (In case of listed companies)
15.5. Recent Developments
15.6. SWOT Analysis
15.6.1. Agilent Technologies,
Inc.
15.6.2. Atara
Biotherapeutics, Inc.
15.6.3. Burning Rock Biotech
Limited
15.6.4. Exact Sciences Corp.
15.6.5. F. Hoffmann-La Roche
Ltd.
15.6.6. Fulgent Genetics,
Inc.
15.6.7. Genecast
Biotechnology Co., Ltd.
15.6.8. Guardant Health,
Inc.
15.6.9. Illumina, Inc. (GRAIL, LLC.)
15.6.10. Konica Minolta, Inc. (Ambry Genetics.)
16. Strategic Recommendations
17. About Us & Disclaimer